GlassScriptPhysician profile
Wesley John Chang
NPI 1174593453
$5,327.51
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $742 · 2021: $1,726 · 2022: $676 · 2023: $733 · 2024: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,083.37 | 2019-2024 | Farxiga, Breztri |
| Amgen INC. | $1,029.44 | 2019-2024 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $674.33 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $480.52 | 2021-2023 | Ubrelvy |
| Pfizer INC. | $410.98 | 2019-2024 | |
| Novo Nordisk INC | $375.74 | 2019-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.79 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $134.23 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $115.40 | 2022-2023 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $101.52 | 2021 | |
| Exact Sciences Corporation | $100.09 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $97.16 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $92.88 | 2022 | |
| Allergan, INC. | $77.47 | 2020 | |
| Novartis Pharmaceuticals Corporation | $55.68 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $39.59 | 2019-2020 | |
| Glaxosmithkline, LLC. | $33.70 | 2019 | |
| Upsher-Smith Laboratories LLC | $33.50 | 2021 | |
| Merck Sharp & Dohme LLC | $27.64 | 2019-2020 | |
| Abbott Laboratories | $27.09 | 2021 | |
| Boston Scientific Corporation | $24.42 | 2024 | |
| Idorsia Pharmaceuticals US INC | $18.00 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $17.76 | 2019 | |
| Medline Industries LP | $17.36 | 2024 | |
| Sebela Pharmaceuticals INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.